Chunghwa Chemical Synthesis & Biotech Co Ltd
TWSE:1762
Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the manufacture, research and development of active pharmaceutical ingredients (API). The company is headquartered in Taipei, New Taipei. The company went IPO on 2009-12-10. The firm's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The firm distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the manufacture, research and development of active pharmaceutical ingredients (API). The company is headquartered in Taipei, New Taipei. The company went IPO on 2009-12-10. The firm's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The firm distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
